State Of New Jersey Common Pension Fund D Biocryst Pharmaceuticals Inc Transaction History

State Of New Jersey Common Pension Fund D

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	BUY	$6.96 - $8.81 $362,518 - $458,877	52,086 Added 21.92%	289,701 $2.04 Million
Q1 2023 Apr 26, 2023	BUY	$7.94 - $11.84 $393,951 - $587,453	49,616 Added 26.39%	237,615 $1.98 Million
Q4 2022 Feb 01, 2023	BUY	$10.5 - $14.2 $237,909 - $321,743	22,658 Added 13.7%	187,999 $2.16 Million
Q3 2022 Oct 28, 2022	SELL	$10.79 - $14.81 $909,575 - $1.25 Million	-84,298 Reduced 33.77%	165,341 $2.08 Million
Q2 2022 Aug 04, 2022	BUY	$7.89 - $17.88 $846,297 - $1.92 Million	107,262 Added 75.34%	249,639 $2.64 Million
Q1 2022 May 03, 2022	SELL	$11.56 - $19.76 $1.08 Million - $1.85 Million	-93,840 Reduced 39.73%	142,377 $2.32 Million
Q4 2021 Jan 31, 2022	BUY	$11.18 - $15.46 $573,835 - $793,515	51,327 Added 27.76%	236,217 $3.27 Million
Q3 2021 Oct 27, 2021	BUY	$14.21 - $17.65 $170,363 - $211,605	11,989 Added 6.93%	184,890 $2.66 Million
Q2 2021 Jul 23, 2021	BUY	$9.5 - $17.24 $692,559 - $1.26 Million	72,901 Added 72.9%	172,901 $2.73 Million
Q1 2021 Apr 27, 2021	BUY	$7.37 - $13.61 $737,000 - $1.36 Million	100,000 New	100,000 $1.02 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.